Academic Editor: Robert C. Hendel
Background: Perioperative anticoagulation management with uninterrupted
or minimally interrupted anticoagulation during atrial fibrillation (AF) ablation
is thought to be critical to minimize thromboembolic complications. Protamine is
often administered to neutralize the effects of heparin and expedite vascular
hemostasis post-procedure. Objective: We performed a systematic review
and meta-analysis to determine the effectiveness of protamine to expedite
vascular hemostasis and ambulation in patients undergoing AF ablation.
Methods: Electronic searches on PubMed, The Cochrane Library, EMBASE,
EBSCO, Web of Science, and CINAHL databases from the inception through August 7,
2021, were performed. The primary outcomes included—time to hemostasis
(minutes) and time to ambulation (minutes). The secondary outcomes included - any
vascular complications (excluding minor hematoma), minor hematoma, or
cerebrovascular accidents (CVA). Results: A total of 5 eligible studies
(3 retrospective cohort studies and two randomized trials) consisting of 1012
patients (515 patients received protamine group and 497 patients did not receive
protamine group) were included in the meta-analysis. There was a significant
reduction in time to ambulation [weighted mean difference (WMD) –176.6 minutes,
95% Confidence interval (CI) –266.9 to –86.3; p
Therapeutic anticoagulation with unfractionated heparin (UFH) during atrial fibrillation (AF) ablation is critical to minimize procedure-related thromboembolic complications [1]. The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE, an expert consensus statement on catheter ablation of AF, recommends protamine to neutralize effects of heparin and hasten hemostasis to avoid vascular complications such as aneurysm, fistula, and hematoma (Class IIa, based on moderate quality of evidence) [1]. However, its safety profile and efficacy in promoting faster patient recovery are still unclear. We performed a systematic review and meta-analysis to determine the effectiveness of protamine to expedite vascular hemostasis and ambulation in patients undergoing AF ablation.
A systematic search on PubMed, The Cochrane Library, EMBASE was done using the keywords: “protamine” and “atrial fibrillation ablation”. Two investigators (JK and KS) independently performed the literature search (using PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov from inception to October 20th, 2021) and screened all titles and full-text versions of all relevant studies that met study inclusion criteria (Supplementary Fig. 1).
We used the following keywords and medical subject heading: “Protamine”, “atrial fibrillation ablation”, “AF ablation”. This meta-analysis was performed according to the PRISMA guidelines and was prospectively enrolled in the PROSPERO database (ID 288480).
The eligibility criteria for our systematic review and meta-analysis included: (1) all studies reporting outcomes of the use of protamine in patients with AF ablation (2) studies that included human subjects. We included studies only in the English language. Case reports, abstracts, editorial, or systematic reviews were excluded. The data from the included studies were extracted using a standardized protocol and a data extraction form. Any discrepancies between the two investigators were resolved with a consultation with the co-senior investigators (DL and JG). The following data was extracted from the eligible studies: author name, study design, publication year, follow-up duration, number of patients, age, gender, co-morbid conditions, anticoagulation type, ablation strategy, procedural characteristics and post ablation management. The Cochrane – Risk bias assessment tool was used to appraise the quality of randomized studies (Supplementary Table 1), while the Newcastle Ottawa Risk bias assessment tool was used to appraise the quality of the included studies (Supplementary Table 2). Studies’ quality was rated as good, fair, and poor by awarding stars in each domain. A “good” quality score required 3 or 4 stars in the selection, 1 or 2 stars in comparability, and 2 or 3 stars in outcomes. A “fair” quality score required two stars in the selection, 1 or 2 stars in comparability, and 2 or 3 stars in outcomes. A “poor” quality score reflected 0 or 1 star(s) in selection, or 0 stars in comparability, or 0 or 1 star(s) in outcomes.
Statistical analysis was performed using meta-package for R version 4.0
and Rstudio version 1.2. Mantel-Haenszel risk ratio (RR) random-effects model was
used to summarize data between two groups. Heterogeneity of the effect size among
the included studies was assessed by Higgins I-squared (I
The primary outcomes included—time to hemostasis (minutes) and time to ambulation (minutes). The secondary outcomes included—any vascular complications (composite of any major hematoma, hematomas requiring blood transfusion, pseudoaneurysm, arteriovenous fistula excluding minor hematoma), minor hematoma, or cerebrovascular accidents (CVA).
A total of 5 eligible studies (3 retrospective cohort studies and two randomized
trials) consisting of 1012 patients (515 patients received protamine group and
497 patients did not receive protamine group) were included in the meta-analysis
[2, 3, 4, 5, 6]. Overall, the mean age was 62.9
Variables | Conte et al. [2], 2014 (n = 107) | Ghannam et al. [4], 2018 (n = 150) | Gurses et al. [3], 2015 (n = 380) | Rolantova et al. [5], 2018 (n = 81) | Yasar et al. [6], 2019 (n = 294) | ||||||
Protamine (n = 54) | No protamine (n = 53) | Protamine (n = 77) | No protamine (n = 73) | Protamine (n = 188) | No protamine (n = 192) | Protamine (n = 40) | No protamine (n = 41) | Protamine (n = 156) | No protamine (n = 138) | ||
Study design | Retrospective cohort | Randomized controlled trial | Retrospective cohort | Randomized controlled trial | Multicenter retrospective cohort | ||||||
Age, years (mean |
60 |
58 |
63 |
66 |
55 (27–76) | 57 (20–86) | 61.2 |
64.5 |
64.2 |
63 | |
Male, n (%) | 33 (61%) | 31 (58%) | 46 (60%) | 48 (66%) | 95 (50.5%) | 88 (45.8%) | 23 (58%) | 22 (54%) | 100 (64.1%) | 89 (64.5%) | |
Diabetes mellitus, n (%) | 4 (7%) | 5 (9%) | n/a | n/a | 31 (16.5%) | 25 (13%) | 5 (13%) | 7 (17%) | 24 (19.8%) | 32 (23.2%) | |
Hypertension, n (%) | 21 (39%) | 23 (43%) | n/a | n/a | 81 (43.1%) | 94 (49%) | 25 (63%) | 33 (81%) | 91 (75.2%) | 106 (76.8%) | |
Coronary artery disease, n (%) | 7 (13%) | 6 (11%) | n/a | n/a | 17 (9%) | 29 (15.1%) | 5 (13%) | 5 (13%) | 33 (27.3%) | 27 (19.6%) | |
Type of atrial fibrillation | |||||||||||
Paroxysmal, n (%) | 100% | 100% | 40 (52%) | 34 (46%) | 146 (88%) | 163 (85%) | 28 (70%) | 23 (56%) | 92 (59%) | 54 (39%) | |
Persistent, n (%) | - | - | 34 (44%) | 31 (42%) | 42 (22%) | 29 (15%) | 12 (30%) | 18 (44%) | 64 (41%) | 84 (61%) | |
Anticoagulation use | 52 (27.7%) | 60 (31.3%) | |||||||||
Warfarin | 31 (57%) | 32 (60%) | 14 (18%) | 14 (19%) | n/a | n/a | 40 (100%) | 41 (100%) | 22 (14.1%) | 30 (21.7%) | |
NOAC | 9 (17%) | 9 (17%) | 63 (82%) | 59 (81%) | n/a | n/a | 116 (74.4%) | 95 (68.8%) | |||
Aspirin | 14 (26%) | 12 (23%) | - | - | n/a | n/a | n/a | n/a | |||
LVEF (mean |
58 |
55 |
n/a | n/a | 65.9 |
65.9 |
66.3 |
66 |
n/a | n/a | |
LA size, mm (mean |
41 |
42 |
n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
CHA2DS2-VASc score (mean |
1.8 |
1.6 |
2.1 |
2.2 |
n/a | n/a | 2.2 |
2.1 |
n/a | n/a | |
HAS-BLED score (mean |
1.0 |
0.9 |
n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Pre-ablation anticoagulation strategies | – | uninterrupted warfarin or minimally interrupted oral anticoagulants | discontinuing oral anticoagulants or warfarin 48 hours before; bridging with low molecular weight heparin | discontinuing oral anticoagulants or warfarin 48 hours before; bridging with low molecular weight heparin | uninterrupted warfarin or minimally interrupted oral anticoagulants | ||||||
Ablation type | |||||||||||
Radiofrequency, n (%) | - | - | 57 (74%) | 55 (75%) | - | - | 100% | 100% | 132 (85%) | 100% | |
Cryoballoon, n (%) | 100% | 100% | 20 (26%) | 18 (25%) | 100% | 100% | - | - | 24 (15%) | - | |
Total heparin dose, U (mean |
8900 |
8700 |
23724 |
21541 |
7808 |
7827 |
19500 |
18900 |
239 |
208 | |
Protamine administration | 1 mg/100 U of heparin given at the end of procedure | - | 1 mg/100 U of heparin given at the end of procedure | - | 1 mg/100 U of heparin given at the end of procedure | - | Fixed dose per total heparin and last ACT given at the end of procedure | - | Dose at operator’s discretion | - | |
Sheath removal process | At the end of protamine administration | After ACT |
After ACT |
At the end of protamine administration | 90 minutes after last heparin dose without ACT | At the end of protamine administration | After ACT |
After ACT |
Suture with F8S or SCT prior to sheath removal | ||
Hemostasis-to-ambulation protocol | Manual compression and 10-hr bed rest and groin bandage | Manual compression and 4-hr bed rest | Manual compression and 6-hr bed rest and 12-hr groin bandage | Manual compression and 12-hr bed rest | Manual compression and 4-hr bedrest for both group | ||||||
Procedural time (minutes) | |||||||||||
Total time (mean |
93 |
89 |
199 |
214 |
73.6 |
71.3 |
111 |
104 |
177.1 |
213.2 | |
Fluoroscopy time (mean |
14 |
13 |
n/a | n/a | 15 |
15.1 |
4.8 |
5.1 |
n/a | n/a | |
Post-procedural time (minutes) | |||||||||||
Time to sheath removal (mean |
n/a | n/a | n/a | n/a | 6.3 |
96.3 |
n/a | n/a | n/a | n/a | |
Time to hemostasis (mean |
n/a | n/a | 123 |
260 |
6.1 |
6.1 |
15.9 |
21.9 |
n/a | n/a | |
Time to ambulation (mean |
687 |
725 |
316 |
480 |
366.3 |
456.3 |
792 |
1218 |
n/a | n/a | |
Reported vascular complications | Hematoma, bleeding | Bleeding, hematoma | Hematoma, pseudoaneurysm, AVF | Hematoma, pseudoaneurysm, AVF, bleeding | Hematoma, pseudoaneurysm, AVF, suture failure | ||||||
Adverse events | |||||||||||
Any Vascular complication, n (%) | 0 | 6 (11%) | 6 (8%) | 4 (5%) | 2 (1.1%) | 12 (6.3%) | 5 (12.5%) | 14 (34%) | 2 (1%) | 1 (0.6%) | |
Minor hematoma, n (%) | 0 | 5 (9%) | 5 (6%) | 4 (5%) | 1 (0.5%) | 8 (4%) | 4 (10%) | 12 (29.2%) | 1 (0.6%) | 0 | |
Cerebrovascular accident, n (%) | n/a | n/a | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | n/a | n/a | |
Adverse reaction to protamine | 0 | - | 1 (1%) | - | 1 (0.5%) | - | 0 | - | 1 (0.6%) | - | |
ACT, Activated clotting time; AVF, Arteriovenous fistula;
CHA2DS2-VASc, congestive heart failure, hypertension, age |
There was a significant reduction in time to ambulation [weighted mean
difference (WMD) –176.6 minutes, 95% CI –266.9 to –86.3; p
Forest plot demonstrating the WMD of time to ambulate
and time to hemostasis post-procedure between patients who received protamine and
patients who did not. The total number of participants mean and SD for time to
ambulation and time to hemostasis are reported for each study individually.
Square with horizontal line represents WMD and 95% CI for each individual study,
with square size reflecting the statistical weight of the study using the
random-effects model. The diamond represents pooled WMD and 95% CI for each
outcome. Heterogeneity (I
Forest plot demonstrating risk ratio of adverse events
post-procedure between patients who received protamine and patients who did not.
The total number of participants and number of events for any vascular
complications, minor hematoma, and cerebrovascular accident are reported for each
study individually. Square with horizontal line represents RR and 95% CI for
each individual study with square size reflecting the statistical weight of the
study using the random-effects model. Diamond demonstrates pooled RR and 95% CI
for each outcome. Heterogeneity (I
The results of our pooled analysis demonstrate a significant reduction in time to hemostasis and time to ambulation with a mean of 13 minutes and 176 minutes, respectively, with the use of protamine following AF ablation. There was a positive trend in decreasing the risk of vascular complications and CVA with protamine administration, although this difference did not reach statistical significance due to inadequate power and low event rates (Fig. 3).
Protamine administration after catheter ablation of atrial fibrillation.
Vascular access complications, including bleeding, hematoma, arteriovenous
fistula, or pseudoaneurysm, are major adverse events in patients undergoing AF
ablation due to an aggressive anticoagulation protocol [7, 8, 9]. To reduce the risk
of bleeding events, ACT must return from ACT goal during the procedure (300–350
s) to normal range (
Taken together, our study provides the best available evidence to date regarding the effect of protamine administration on sheath removal time, immobilization time, and the risk of adverse clinical events—finding which might be clinically relevant and can reduce intensive care monitoring time, and consequently health care cost utilization. This meta-analysis is limited by possible patient-physician selection bias, lack of patient-level data, heterogeneous study design (different preablation anticoagulation management strategies) and follow-up period, and lack of long-term outcomes and imaging data. Finally, these results cannot be extrapolated to groins closed with commercially available vascular closure devices.
Conceptualization: JK, KS, MT; methodology, JK, KS, MT, JG; software, JK, KS; validation, KS, MT, JG; formal analysis, RB, RM, TC; investigation, MT, RB, JG; resources, KS, JG; data curation, JK, KS; writing—original draft preparation, JK, TC, DL; writing—review and editing, DL, JG; visualization, RB, TC, RM; supervision, DL, JG; project administration RM, DL, JG. All authors have read and agreed to the published version of the manuscript.
Not applicable.
We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.
This research received no external funding.
The authors declare no conflict of interest.